NCT04763265View on ClinicalTrials.gov

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

June 24, 2020

Primary Completion Date

November 5, 2020

Study Completion Date

February 1, 2021

Conditions
Frown Lines
Interventions
BIOLOGICAL

"Botulinum toxin A BoNT/A-DP"

To assess the efficacy of treatment with BoNT/A-DP in reducing the severity of glabellar frown lines at maximum frown.

BIOLOGICAL

"Botulinum toxin A Botox Cosmetics"

To assess the efficacy of treatment with Botox Cosmetics in reducing the severity of glabellar frown lines at maximum frown.

Trial Locations (5)

1010

Monika Sulovsky, Vienna

33146

Skin Research Institute LLC, Coral Gables

90404

ATS Clinical Research, Santa Monica

L6J7W5

Institute Of Cosmetic, Oakville

M5R3N8

Sweat Clinics of Canada, Toronto

Sponsors

Lead Sponsor

Croma-Pharma GmbH
All Listed Sponsors
collaborator

Hugel

INDUSTRY

lead

Croma-Pharma GmbH

INDUSTRY

NCT04763265 - Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines | Biotech Hunter | Biotech Hunter